First Trust Advisors LP Beam Therapeutics Inc. Transaction History

First Trust Advisors LP

$108 Billion
Q1 2025

A detailed history of First Trust Advisors LP transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 99,084 shares of BEAM stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

99,084

Previous 25,595 287.12%

Holding current value

$1.8 Million

Previous $634,000 205.21%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$19.53 - $34.09 $1.44 Million - $2.51 Million	73,489 Added 287.12%	99,084 $1.94 Million
Q4 2024 Feb 13, 2025	BUY	$21.55 - $30.35 $164,275 - $231,358	7,623 Added 42.42%	25,595 $634,000
Q3 2024 Nov 13, 2024	SELL	$22.57 - $33.14 $33 Million - $48.5 Million	-1,464,299 Reduced 98.79%	17,972 $440,000
Q2 2024 Aug 13, 2024	BUY	$21.22 - $32.66 $31.5 Million - $48.4 Million	1,482,271 New	1,482,271 $34.7 Million
Q4 2022 Feb 09, 2023	BUY	$36.73 - $51.6 $1.93 Million - $2.71 Million	52,584 New	52,584 $2.06 Million
Q2 2022 Aug 12, 2022	SELL	$29.86 - $62.36 $237,536 - $496,073	-7,955 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$53.73 - $82.16 $47,013 - $71,890	-875 Reduced 9.91%	7,955 $456,000
Q4 2021 Feb 08, 2022	SELL	$68.02 - $99.06 $5.19 Million - $7.56 Million	-76,276 Reduced 89.62%	8,830 $704,000
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $2.01 Million - $3.18 Million	23,765 Added 38.74%	85,106 $7.41 Million
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $3.93 Million - $7.9 Million	61,341 New	61,341 $7.9 Million

Others Institutions Holding BEAM

# of Institutions

258

Shares Held

93.6M

Call Options Held

425K

Put Options Held

309K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.28B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.

Account

First Trust Advisors LP Beam Therapeutics Inc. Transaction History